 | Up a level |
Poliaková Turan, Michaela; Riedo, Rahel; Medo, Matúš; Pozzato, Chiara; Friese-Hamim, Manja; Koch, Jonas Paul; Coggins, Si'Ana A; Li, Qun; Kim, Baek; Albers, Joachim; Aebersold, Daniel M; Zamboni, Nicola; Zimmer, Yitzhak; Medová, Michaela (2024). E2F1-associated purine synthesis pathway is a major component of the MET-DNA damage response network. Cancer research communications, 4(7), pp. 1863-1880. American Association for Cancer Research 10.1158/2767-9764.CRC-23-0370
Deng, Haibin; Ge, Huixiang; Dubey, Christelle; Losmanova, Tereza; Medova, Michaela; Konstantinidou, Georgia; Mutlu, Seyran Mathilde; Birrer, Fabienne Esther; Brodie, Tess Melinda; Stroka, Deborah; Wang, Wenxiang; Peng, Ren-Wang; Dorn, Patrick; Marti, Thomas Michael (2023). An optimized protocol for the generation and monitoring of conditional orthotopic lung cancer in the KP mouse model using an adeno-associated virus vector compatible with biosafety level 1. Cancer immunology, immunotherapy : CII, 72(12), pp. 4457-4470. Springer 10.1007/s00262-023-03542-z
Hayrapetyan, Liana; Bouteiller, Sofiane; Quintin, Aurélie; Riedo, Rahel; Degen, Peter; Aebersold, Daniel; Medo, Matúš; Adamantidis, Antoine; Levitt, Pat; Zimmer, Yitzhak; Medova, Michaela (2023). MICE LACKING A NOVEL PHOSPHOSITE S1014 ON THE MET RECEPTOR TYROSINE KINASE DISPLAY ASD-ASSOCIATED BEHAVIORAL PATTERN. IBRO neuroscience reports, 15(S1), S99-S99. Elsevier 10.1016/j.ibneur.2023.08.079
Esposito, Roberta; Lanzos, Andrés; Uroda, Tina; Ramnarayanan, Sunandini; Büchi, Isabel; Polidori, Taisia; Guillen-Ramirez, Hugo; Mihaljevic, Ante; Merlin, Bernard Mefi; Mela, Lia; Zoni, Eugenio; Hovhannisyan, Lusine; McCluggage, Finn; Medo, Matúš; Basile, Giulia; Meise, Dominik F; Zwyssig, Sandra; Wenger, Corina; Schwarz, Kyriakos; Vancura, Adrienne; ... (2023). Author Correction: Tumour mutations in long noncoding RNAs enhance cell fitness. Nature communications, 14(1), p. 5463. Nature Publishing Group 10.1038/s41467-023-41288-5
Esposito, Roberta; Lanzós, Andrés; Uroda, Tina; Ramnarayanan, Sunandini; Büchi, Isabel; Polidori, Taisia; Guillen-Ramirez, Hugo; Mihaljevic, Ante; Merlin, Bernard Mefi; Lia, Mela; Zoni, Eugenio; Hovhannisyan, Lusine; McCluggage, Finn; Medo, Matúš; Basile, Giulia; Meise, Dominik F; Zwyssig, Sandra; Wenger, Corina; Schwarz, Kyriakos; Vancura, Adrienne; ... (2023). Tumour mutations in long noncoding RNAs enhance cell fitness. Nature communications, 14(1), p. 3342. Nature Publishing Group 10.1038/s41467-023-39160-7
Koch, Jonas P; Roth, Selina M; Quintin, Aurélie; Gavini, Jacopo; Orlando, Eleonora; Riedo, Rahel; Pozzato, Chiara; Hayrapetyan, Liana; Aebersold, Ruedi; Stroka, Deborah M; Aebersold, Daniel M; Medo, Matúš; Zimmer, Yitzhak; Medova, Michaela (2023). A DNA-PK phosphorylation site on MET regulates its signaling interface with the DNA damage response. Oncogene, 42(26), pp. 2113-2125. Nature Publishing Group 10.1038/s41388-023-02714-6
Hovhannisyan, Lusine; Riether, Carsten; Aebersold, Daniel M; Medova, Michaela; Zimmer, Yitzhak (2023). CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks. Molecular cancer, 22(1), p. 82. BioMed Central 10.1186/s12943-023-01775-1
Dennstädt, Fabio; Glatzer, Markus; Medová, Michaela; Putora, Paul Martin (2023). In Reply to Raaijmakers et al. International journal of radiation oncology, biology, physics, 115(4), p. 1005. Elsevier 10.1016/j.ijrobp.2022.11.019
Orlando, Eleonora; Medo, Matúš; Bensimon, Ariel; Quintin, Aurélie; Riedo, Rahel; Roth, Selina M; Riether, Carsten; Marti, Thomas M; Aebersold, Daniel M; Medová, Michaela; Aebersold, Ruedi; Zimmer, Yitzhak (2023). Correction: An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies. Cellular and molecular life sciences : CMLS, 80(4), p. 85. Springer 10.1007/s00018-023-04725-8
Dennstädt, Fabio; Medova, Michaela; Putora, Paul Martin; Glatzer, Markus (2023). Parameters of the Lyman model for calculation of normal tissue complication probability: a systematic literature review. International journal of radiation oncology, biology, physics, 115(3), pp. 696-706. Elsevier 10.1016/j.ijrobp.2022.08.039
Zabini, Adam; Zimmer, Yitzhak; Medová, Michaela (2023). Beyond keratinocyte differentiation: emerging new biology of small proline-rich proteins. Trends in cell biology, 33(1), pp. 5-8. Elsevier 10.1016/j.tcb.2022.08.002
Schanne, Daniel H; Koch, Alexander; Elicin, Olgun; Giger, Roland; Medová, Michaela; Zimmer, Yitzhak; Aebersold, Daniel M (2022). Prognostic and Predictive Biomarkers in Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy-A Systematic Review. Biomedicines, 10(12) MDPI 10.3390/biomedicines10123288
Orlando, Eleonora; Medo, Matúš; Bensimon, Ariel; Quintin, Aurélie; Riedo, Rahel; Roth, Selina M; Riether, Carsten; Marti, Thomas M; Aebersold, Daniel M; Medova, Michaela; Aebersold, Ruedi; Zimmer, Yitzhak; quintin, a (2022). An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies. Cellular and molecular life sciences : CMLS, 80(1), p. 6. Springer 10.1007/s00018-022-04634-2
Melin, Nicolas; Sánchez-Taltavull, Daniel; Fahrner, René; Keogh, Adrian; Dosch, Michel; Büchi, Isabel; Zimmer, Yitzhak; Medová, Michaela; Beldi, Guido; Aebersold, Daniel M.; Candinas, Daniel; Stroka, Deborah (2021). Synergistic effect of the TLR5 agonist CBLB502 and its downstream effector IL-22 against liver injury. Cell death & disease, 12(4), p. 366. Nature Publishing Group 10.1038/s41419-021-03654-3
Bosch-Guiteras, Núria; Uroda, Tina; Guillen-Ramirez, Hugo A.; Riedo, Rahel; Gazdhar, Amiq; Esposito, Roberta; Pulido-Quetglas, Carlos; Zimmer, Yitzhak; Medová, Michaela; Johnson, Rory (2021). Enhancing CRISPR deletion via pharmacological delay of DNA-PKcs. Genome research, 31(3), pp. 461-471. Cold Spring Harbor, N.Y 10.1101/gr.265736.120
Medova, Michaela; Medo, Matúš; Hovhannisyan, Lusine; Muñoz-Maldonado, Carmen; Aebersold, Daniel M.; Zimmer, Yitzhak (2020). DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventions. Pharmacology & therapeutics, 215, p. 107617. Elsevier 10.1016/j.pharmthera.2020.107617
Dommann, Noëlle; Sánchez Taltavull, Daniel; Eggs, Linda; Birrer, Fabienne Esther; Brodie, Tess; Salm, Lilian; Baier, Felix Alexander; Medova, Michaela; Humbert, Magali; Tschan, Mario; Beldi, Guido; Candinas, Daniel; Stroka, Deborah (2020). The LIM Protein Ajuba Augments Tumor Metastasis in Colon Cancer. Cancers, 12(7) MDPI AG 10.3390/cancers12071913
Bensimon, Ariel; Koch, Jonas P.; Francica, Paola; Roth, Selina M.; Riedo, Rahel; Glück, Astrid A.; Orlando, Eleonora; Blaukat, Andree; Aebersold, Daniel M.; Zimmer, Yitzhak; Aebersold, Ruedi; Medová, Michaela (2020). Deciphering MET-dependent modulation of global cellular responses to DNA damage by quantitative phosphoproteomics. Molecular oncology, 14(6), pp. 1185-1206. Elsevier 10.1002/1878-0261.12696
Koch, Jonas P.; Aebersold, Daniel M.; Zimmer, Yitzhak; Medová, Michaela (2020). MET targeting: time for a rematch. Oncogene, 39(14), pp. 2845-2862. Springer Nature 10.1038/s41388-020-1193-8
Nisa, Lluís; Francica, Paola; Giger, Roland; Medo, Matúš; Eliçin, Olgun; Friese-Hamim, Manja; Wilm, Claudia; Stroh, Christopher; Bojaxhiu, Beat; Quintin, Aurélie; Caversaccio, Marco D.; Dettmer, Matthias S.; Buchwalder, Mélanie; Brodie, Tess M.; Aebersold, Daniel M.; Zimmer, Yitzhak; Carey, Thomas E.; Medova, Michaela (2020). Targeting the MET receptor tyrosine kinase as a strategy for radiosensitization in loco-regionally advanced head and neck squamous cell carcinoma. Molecular cancer therapeutics, 19(2), pp. 614-626. American Association for Cancer Research AACR 10.1158/1535-7163.MCT-18-1274
Zimmer, Yitzhak; Reinhardt, Hans Christian; Medová, Michaela (2020). Editorial: Exploiting DNA Damage Response in the Era of Precision Oncology. Frontiers in oncology, 10, p. 611127. Frontiers Research Foundation 10.3389/fonc.2020.611127
Medo, Matúš; Aebersold, Daniel M.; Medova, Michaela (2019). ProtRank: bypassing the imputation of missing values in differential expression analysis of proteomic data. BMC bioinformatics, 20(1), p. 563. BioMed Central 10.1186/s12859-019-3144-3
Gavini, Jacopo; Dommann, Noëlle; Jakob, Manuel O.; Keogh, Adrian; Bouchez, Laure C; Karkampouna, Sofia; Kruithof-de Julio, Marianna; Medova, Michaela; Zimmer, Yitzhak; Schläfli, Anna M; Tschan, Mario P.; Candinas, Daniel; Stroka, Deborah; Banz, Vanessa (2019). Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma. Cell death & disease, 10(10), p. 749. Springer Nature 10.1038/s41419-019-1989-z
Poliaková, Michaela; Felser, Andrea; Pierzchala, Katarzyna; Nuoffer, Jean-Marc; Aebersold, Daniel; Zimmer, Yitzhak; Zamboni, Nicola; Medova, Michaela (2019). Metabolomics reveals tepotinib-related mitochondrial dysfunction in MET activating mutations-driven models. FEBS journal, 286(14), pp. 2692-2710. Wiley-Blackwell 10.1111/febs.14852
Orlando, Eleonora; Aebersold, Daniel; Medova, Michaela; Zimmer, Yitzhak (2019). Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase. Cancer letters, 443, pp. 189-202. Elsevier 10.1016/j.canlet.2018.12.001
Muñoz-Maldonado, Carmen; Zimmer, Yitzhak; Medova, Michaela (2019). A Comparative Analysis of Individual RAS Mutations in Cancer Biology. Frontiers in oncology, 9, p. 1088. Frontiers Research Foundation 10.3389/fonc.2019.01088
Nisa, Lluís; Barras, David; Medova, Michaela; Aebersold, Daniel M.; Medo, Matúš; Poliaková, Michaela; Koch, Jonas; Bojaxhiu, Beat; Eliçin, Olgun; Dettmer, Matthias S.; Angelino, Paolo; Giger, Roland; Borner, Urs; Caversaccio, Marco D.; Carey, Thomas E; Ho, Liza; McKee, Thomas A; Delorenzi, Mauro; Zimmer, Yitzhak (2018). Comprehensive Genomic Profiling of Patient-matched Head and Neck Cancer Cells: A Preclinical Pipeline for Metastatic and Recurrent Disease. Molecular cancer research, 16(12), pp. 1912-1926. American Association for Cancer Research AACR 10.1158/1541-7786.MCR-18-0056
Glück, Astrid Andreina; Orlando, Eleonora; Leiser, Dominic; Poliakova, Michaela; Nisa Hernández, Lluís; Quintin, Aurélie; Gavini, Jacopo; Keogh-Stroka, Deborah M.; Berezowska, Sabina; Bubendorf, Lukas; Blaukat, Andree; Aebersold, Daniel; Medova, Michaela; Zimmer, Yitzhak (2018). Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1α levels under hypoxia. Oncogene, 37(30), pp. 4181-4196. Nature Publishing Group 10.1038/s41388-018-0256-6
Brodie, Tess; Tosevski, Vinko; Medova, Michaela (2018). OMIP-045: Characterizing human head and neck tumors and cancer cell lines with mass cytometry. Cytometry Part A, 93(4), pp. 406-410. Wiley 10.1002/cyto.a.23336
Poliakova, Michaela; Aebersold, Daniel; Zimmer, Yitzhak; Medova, Michaela (2018). The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer. Molecular cancer, 17(1), p. 27. BioMed Central 10.1186/s12943-018-0798-9
Melin, Nicolas; Fahrner, René; Keogh, Adrian; Medova, Michaela; Zimmer, Yitzhak; Aebersold, Daniel; Candinas, Daniel; Beldi, Guido; Keogh-Stroka, Deborah M. (2018). Direct and indirect hepatoprotective mechanism of CBLB502 a TLR5 agonist. Journal of hepatology, 68, S140-S141. Elsevier 10.1016/S0168-8278(18)30497-5
Nisa Hernández, Lluís; Häfliger, Pascal; Poliakova, Michaela; Giger, Roland; Francica, Paola; Aebersold, Daniel; Charles, Roch-Philippe; Zimmer, Yitzhak; Medova, Michaela (2017). PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models. Molecular cancer, 16(1), p. 93. BioMed Central 10.1186/s12943-017-0660-5
Nita, Izabela Magdalena; Hostettler, Katrin; Tamò, Luca Giuseppe Athos; Medova, Michaela; Bombaci, Giuseppe; Zhong, Jun; Allam, Ramanjaneyulu; Zimmer, Yitzhak; Roth, Michael; Geiser, Thomas; Gazdhar, Amiq (2017). Hepatocyte growth factor secreted by bone marrow stem cell reduce ER stress and improves repair in alveolar epithelial II cells. Scientific Reports, 7(41901), p. 41901. Nature Publishing Group 10.1038/srep41901
Francica, Paola; Aebersold, Daniel; Medova, Michaela (2017). Senescence as biologic endpoint following pharmacological targeting of receptor tyrosine kinases in cancer. Biochemical pharmacology, 126, pp. 1-12. Elsevier 10.1016/j.bcp.2016.08.022
Francica, Paola; Nisa Hernandez, Lluis; Aebersold, Daniel; Langer, Rupert; Bladt, Friedhelm; Blaukat, Andree; Keogh-Stroka, Deborah M.; Martínez, María Rodríguez; Zimmer, Yitzhak; Medova, Michaela (2016). Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer. Clinical cancer research, 22(21), pp. 5322-5336. American Association for Cancer Research 10.1158/1078-0432.CCR-15-2987
Medova, Michaela (2016). Tepotinib. Selective MET receptor tyrosine kinase inhibitor, Treatment of lung and liver cancers. Drugs of the Future, 41(11), p. 659. Prous Science 10.1358/dof.2016.041.11.2555984
Mikami, K.; Medova, Michaela; Nisa Hernandez, Lluis; Francica, Paola; Glück, Astrid Andreina; Tschan, Mario; Blaukat, A.; Bladt, F.; Aebersold, Daniel; Zimmer, Yitzhak (2015). Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation. Molecular cancer research, 13(12), pp. 1544-1553. American Association for Cancer Research AACR 10.1158/1541-7786.MCR-15-0022
Leiser, Dominic; Medova, Michaela; Mikami, Kei; Nisa Hernandez, Lluis; Keogh-Stroka, Deborah M.; Blaukat, Andree; Bladt, Friedhelm; Aebersold, Daniel; Zimmer, Yitzhak (2015). KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells. Molecular oncology, 9(7), pp. 1434-1446. Elsevier 10.1016/j.molonc.2015.04.001
Piguet, Anne-Christine; Medova, Michaela; Keogh, Adrian; Glück, Astrid Andreina; Aebersold, Daniel; Dufour, Jean-François; Dufour, Jean-François; Zimmer, Yitzhak (2015). Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer. Genes & cancer, 6(7-8), pp. 317-327. Impact Journals
Glück, Astrid Andreina; Aebersold, Daniel; Zimmer, Yitzhak; Medova, Michaela (2015). Interplay between receptor tyrosine kinases and hypoxia signaling in cancer. The international journal of biochemistry & cell biology, 62, pp. 101-114. 10.1016/j.biocel.2015.02.018
Nisa Hernandez, Lluis; Aebersold, Daniel; Giger, Roland; Caversaccio, Marco; Borner, Urs; Medova, Michaela; Zimmer, Yitzhak (2015). Profiling invasiveness in head and neck cancer: recent contributions of genomic and transcriptomic approaches. Cancers, 7(2), pp. 585-597. MDPI AG 10.3390/cancers7020585
Nisa Hernandez, Lluis; Aebersold, Daniel; Giger, Roland; Zimmer, Yitzhak; Medova, Michaela (2014). Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer. Pharmacology & therapeutics, 143(3), pp. 337-349. Elsevier 10.1016/j.pharmthera.2014.04.005
Leiser, Dominic; Pochon, Benoît; Blank Wieslawa, Elzbieta; Francica, Paola; Glück, Astrid; Aebersold, Daniel; Zimmer, Yitzhak; Medova, Michaela (2014). Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation. FEBS letters, 588(5), pp. 653-658. Elsevier 10.1016/j.febslet.2013.12.025
Medova, Michaela; Aebersold, Daniel M.; Zimmer, Yitzhak (2014). The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response - Biological and Clinical Aspects. Cancers, 6(1), pp. 1-27. MDPI AG 10.3390/cancers6010001
Medová, Michaela; Pochon, Benoît; Streit, Bruno; Blank-Liss, Wieslawa; Francica, Paola; Stroka, Deborah; Keogh, Adrian; Aebersold, Daniel M.; Blaukat, Andree; Bladt, Friedhelm; Zimmer, Yitzhak (2013). The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants. Molecular cancer therapeutics, 12(11), pp. 2415-2424. American Association for Cancer Research AACR 10.1158/1535-7163.MCT-13-0151
Humbert, Magali; Medova, Michaela; Aebersold, Daniel; Blaukat, Andree; Bladt, Friedhelm; Fey, Martin; Zimmer, Yitzhak; Tschan, Mario P. (2013). Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells. Biochemical and biophysical research communications, 431(2), pp. 264-269. Academic Press 10.1016/j.bbrc.2012.12.120
Medová, Michaela; Aebersold, Daniel M; Zimmer, Yitzhak (2012). MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks. International journal of cancer, 130(3), pp. 728-34. Malden, Mass.: Wiley-Blackwell 10.1002/ijc.26058
Zimmer, Yitzhak; Vaseva, Angelina V; Medová, Michaela; Streit, Bruno; Blank-Liss, Wieslawa; Greiner, Richard H; Schiering, Nikolaus; Aebersold, Daniel M (2010). Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274. Cancer letters, 289(2), pp. 228-36. Amsterdam: Elsevier 10.1016/j.canlet.2009.08.017
Banz, Vanessa M; Medová, Michaela; Keogh, Adrian; Furer, Cynthia; Zimmer, Yitzhak; Candinas, Daniel; Stroka, Deborah (2009). Hsp90 transcriptionally and post-translationally regulates the expression of NDRG1 and maintains the stability of its modifying kinase GSK3beta. Biochimica et biophysica acta - molecular cell research, 1793(10), pp. 1597-603. New York, N.Y.: Elsevier 10.1016/j.bbamcr.2009.08.002
Ganapathipillai, Suganthini S; Medová, Michaela; Aebersold, Daniel M; Manley, Paul W; Berthou, Sylvie; Streit, Bruno; Blank-Liss, Wieslawa; Greiner, Richard H; Rothen-Rutishauser, Barbara; Zimmer, Yitzhak (2008). Coupling of mutated Met variants to DNA repair via Abl and Rad51. Cancer research, 68(14), pp. 5769-77. Birmingham, Ala.: American Association for Cancer Research AACR 10.1158/0008-5472.CAN-08-1269
Riedo, Rahel; Pilarski, Julia; Elicin, Olgun; Aebersold, D. M.; Stoycheva, Diana; Carl, Sarah; Medova, Michaela (18 September 2023). Immune signature to predict early toxicities of head and neck squamous cell carcinoma patients following multimodal therapy. Strahlentherapie und Onkologie, 11(199), p. 1043. Springer
Schanne, Daniel Hendrik; Koch, Alexander; Eliçin, Olgun; Medova, Michaela; Zimmer, Yitzhak; Aebersold, Daniel Matthias (May 2023). PO-1446 Systematic Review of Prognostic and Predictive Biomarkers in HNSCC Treated with Radiotherapy. Radiotherapy and oncology, 182(S1), S1170-S1171. Elsevier
Hayrapetyan, Liana; Roth, Selina Moara; Hovhannisyan, Lusine; Aebersold, Daniel Matthias; Zimmer, Yitzhak; Medova, Michaela (17 January 2023). p53-dependent treatment response to DNA-PK inhibition in combination with irradiation in head and neck squamous cell carcinoma models. Strahlentherapie und Onkologie, p. 211. Springer
Hovhannisyan, Lusine; Aebersold, Daniel Matthias; Medova, Michaela; Zimmer, Yitzhak (17 January 2023). MET- targeting CAR T cells enhance tumor cell killing and cytokines release in glioma models when combined with radiation therapy. Strahlentherapie und Onkologie, p. 212. Springer
Schanne, Daniel Hendrik; Koch, Alexander; Zimmer, Yitzhak; Medova, Michaela; Eliçin, Olgun; Aebersold, Daniel Matthias (17 January 2023). Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy–A Systematic Review. Strahlentherapie und Onkologie, p. 220. Springer
Hayrapetyan, Liana; Bouteiller, Sofiane; Quintin, Aurélie; Riedo, Rahel; Degen, Peter Methys; Aebersold, Daniel Matthias; Medo, Matúš; Adamantidis, Antoine Roger; Levitt, Pat; Zimmer, Yitzhak; Medova, Michaela (2023). Mice Lacking a Novel Phosphosite on MET Display ASD-Associated Behavior Pattern (Unpublished). In: Annual meeting of the Swiss Society for Neuroscience. Lugano, Switzerland. 09. – 10.06.2023.
Pozzato, Chiara; Koch, Jonas Paul; Riedo, Rahel; Hayrapetyan, Liana; Medo, Matúš; Aebersold, Daniel Matthias; Zimmer, Yitzhak; Medova, Michaela (2023). A newly discovered phosphorylation site of the MET receptor tyrosine kinase, Ser1016, in mediating tumour growth and cancer therapy resistance. (Unpublished). In: BCRC Retreat. Bern, Switzerland. 26.06.2023.
Hayrapetyan, Liana; Degen, Peter Methys; Bouteiller, Sofiane; Riedo, Rahel; Quintin, Aurélie; Aebersold, Daniel Matthias; Medo, Matúš; Adamantidis, Antoine Roger; levitt, pat; Zimmer, Yitzhak; Medova, Michaela (2023). Sex- and strain-dependent dominant behavior in mice lacking the novel S1014 phosphosite on the ASD risk gene MET. (Unpublished). In: Clinical Neuroscience Bern. Bern, Switzerland. 08.09.2023.
